ArticlePloS one2014
Epigenetic upregulation of endogenous VEGF-A reduces myocardial infarct size in mice.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- β-cell-targeted RNA activation of vascular endothelial growth factor-A improves islet transplantation.Signal transduction and targeted therapy · 2026Article
- DNA Methylation: A Key Epigenetic Regulator of Cardiovascular Diseases.Reviews in cardiovascular medicine · 2026Review
- The Role of Epigenetics in Myocardial Infarction: Mechanism, Biomarkers and Therapeutic Potential.Galen medical journal · 2024Review
- Lymphatic insufficiency leads to distinct myocardial infarct content assessed by magnetic resonance TScientific reports · 2023Article
- Construction of Fusion Protein for Enhanced Small RNA Loading to Extracellular Vesicles.Genes · 2023Article
- Article
- Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments.Cells · 2021Review
- Changes in nuclear and cytoplasmic microRNA distribution in response to hypoxic stress.Scientific reports · 2019Article
- Long Non-Coding RNA Modulation of VEGF-A during Hypoxia.Non-coding RNA · 2018Article
- Downregulation of VEGFR3 signaling alters cardiac lymphatic vessel organization and leads to a higher mortality after acute myocardial infarction.Scientific reports · 2018Article
- Article
- Transcriptional gene silencing in humans.Nucleic acids research · 2016Article
- RNA Activation of the Vascular Endothelial Growth Factor Gene (VEGF) Promoter by Double-Stranded RNA and Hypoxia: Role of Noncoding VEGF Promoter Transcripts.Molecular and cellular biology · 2016Article
- Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart.Gene therapy · 2016Article
- Regulation of mammalian transcription and splicing by Nuclear RNAi.Nucleic acids research · 2016Review
- Differential Regulation of Vascular Endothelial Growth Factors by Promoter-targeted shRNAs.Molecular therapy. Nucleic acids · 2015Article
- A New Gene Therapy Approach for Cardiovascular Disease by Non-coding RNAs Acting in the Nucleus.Molecular therapy. Nucleic acids · 2014Review
- The MicroRNA Biology of the Mammalian Nucleus.Molecular therapy. Nucleic acids · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Epigenetherapy" alters epigenetic status of the targeted chromatin and modifies expression of the endogenous therapeutic gene. In this study we used lentiviral in vivo delivery of small hairpin RNA (shRNA) into hearts in a murine infarction model. shRNA complementary to the promoter of vascular endothelial growth factor (VEGF-A) was able to upregulate endogenous VEGF-A expression. Histological and multiphoton microscope analysis confirmed the therapeutic effect in the transduced hearts. Magnetic resonance imaging (MRI) showed in vivo that the infarct size was significantly reduced in the treatment group 14 days after the epigenetherapy. Importantly, we show that promoter-targeted shRNA upregulates all isoforms of endogenous VEGF-A and that an intact hairpin structure is required for the shRNA activity. In conclusion, regulation of gene expression at the promoter level is a promising new treatment strategy for myocardial infarction and also potentially useful for the upregulation of other endogenous genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.